Camrelizumab, formerly known as SHR-1210, represents a significant advancement in cancer immunotherapy , functioning as a antibody that targets the programmed PD-1 receptor. This checkpoint protein, expressed https://mediajx.com/story27965398/camrelizumab-shr-1210-a-deep-dive-into-the-pd-1-blocking-approach